日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bifunctional Metformin-Phenolic Hybrids with Improved Anticancer and Antioxidant Properties: Evaluation on Glioma Cells

具有增强的抗癌和抗氧化特性的双功能二甲双胍-酚类杂合物:对胶质瘤细胞的评价

Delehedde, Caroline; Chocry, Mathieu; Nguyen, Camille; Asteian, Alice; Robin, Maxime; Leloup, Ludovic; Cassien, Mathieu; Mercier, Anne; Culcasi, Marcel; Kovacic, Hervé; Pietri, Sylvia

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

吉西他滨:奥沙利铂耐药性结直肠癌的替代治疗方法

Mathieu Chocry, Ludovic Leloup, Fabrice Parat, Mélissa Messé, Alessandra Pagano, Hervé Kovacic

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

可手术非小细胞肺癌新辅助免疫检查点抑制剂的新兴生物标志物

Pradhan, Monika; Chocry, Mathieu; Gibbons, Don L; Sepesi, Boris; Cascone, Tina

Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile

泛极光激酶抑制剂:一种有前景的去分化脂肪肉瘤靶向疗法,其疗效差异取决于肉瘤分子特征

Jean Camille Mattei, Corinne Bouvier-Labit, Doriane Barets, Nicolas Macagno, Mathieu Chocry, Frédéric Chibon, Philippe Morando, Richard Alexandre Rochwerger, Florence Duffaud, Sylviane Olschwang, Sébastien Salas, Carine Jiguet-Jiglaire

Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway

更正:抑制p38 MAPK逆转结直肠癌细胞系对奥沙利铂的耐药性:钙蛋白酶/Nox1通路参与其中

Chocry, Mathieu; Leloup, Ludovic; Kovacic, Hervé

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway

通过抑制结肠直肠癌细胞系中的 p38 MAPK 逆转对奥沙利铂的耐药性:钙蛋白酶/Nox1 通路的参与

Mathieu Chocry, Ludovic Leloup, Hervé Kovacic